RHUMBLINE ADVISERS - BRAINSTORM CELL THERAPEUTICS ownership

BRAINSTORM CELL THERAPEUTICS's ticker is BCLI and the CUSIP is 10501E201. A total of 82 filers reported holding BRAINSTORM CELL THERAPEUTICS in Q2 2020. The put-call ratio across all filers is 0.48 and the average weighting 0.0%.

Quarter-by-quarter ownership
RHUMBLINE ADVISERS ownership history of BRAINSTORM CELL THERAPEUTICS
ValueSharesWeighting
Q1 2021$108,000
-15.6%
28,2350.0%0.00%
Q4 2020$128,000
-71.2%
28,235
+7.5%
0.00%
-100.0%
Q3 2020$444,000
+37.0%
26,265
-9.1%
0.00%0.0%
Q2 2020$324,00028,9050.00%
Other shareholders
BRAINSTORM CELL THERAPEUTICS shareholders Q2 2020
NameSharesValueWeighting ↓
ABNER HERRMAN & BROCK LLC 241,500$1,093,0000.17%
OCCUDO QUANTITATIVE STRATEGIES LP 90,584$410,0000.13%
EPIQ PARTNERS, LLC 10,550$48,0000.03%
Phoenix Holdings Ltd. 173,683$799,0000.02%
JACOB ASSET MANAGEMENT OF NEW YORK LLC 5,500$25,0000.02%
CFO4Life Group, LLC 12,003$54,0000.02%
HighPoint Advisor Group LLC 15,733$115,0000.01%
VOLORIDGE INVESTMENT MANAGEMENT, LLC 357,761$1,619,0000.01%
Virtu Financial LLC 24,484$111,0000.01%
ETF MANAGERS GROUP, LLC 93,902$435,0000.01%
View complete list of BRAINSTORM CELL THERAPEUTICS shareholders